September 2025 in “Blood Advances” Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.
15 citations
,
July 2022 in “Frontiers in Pharmacology” Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
September 2023 in “Frontiers in bioengineering and biotechnology” JAGGED1 could help regenerate tissues for bone loss and heart damage if delivered correctly.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
May 2023 in “The Journal of Immunology” Expanding CD4+ Tregs can stop hair loss in alopecia areata.
April 2018 in “Journal of Investigative Dermatology” IL-17C is important in inflammatory skin diseases and could be a target for treatment.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
10 citations
,
April 2020 in “PloS one” Lack of Crif1 in hair follicle stem cells slows down hair growth in mice.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
4 citations
,
September 2013 in “Journal of biomolecular structure and dynamics/Journal of biomolecular structure & dynamics” Caribine from traditional Chinese medicine may help treat hair loss.
1 citations
,
September 2019 in “Journal of Investigative Dermatology” The research showed that CRISPR/Cas9 can fix mutations causing a skin disease in stem cells, which then improved skin grafts in mice, but more work on safety and efficiency is needed.
19 citations
,
September 2006 in “Journal of Neurophysiology” Neurosteroids help balance brain signals when certain inhibitions are reduced.
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
41 citations
,
August 2015 in “The FASEB Journal” Blocking the Wnt/β‐catenin pathway can speed up wound healing, reduce scarring, and improve cartilage repair.
November 2016 in “The Molecular Biology Society of Japan”
December 2016 in “Springer eBooks” Chrousos Syndrome is caused by mutations that make the body less sensitive to glucocorticoids, leading to various symptoms and requiring high-dose treatment.
24 citations
,
January 2023 in “Cancer Research” AMPK activation may reduce melanoma risk in red-haired individuals.
March 2026 in “British Journal of Dermatology”
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
123 citations
,
November 2012 in “Stem cells” MicroRNA-302 helps improve the conversion of body cells into stem cells by blocking NR2F2.
Mutations in the PADI3 gene may cause central centrifugal cicatricial alopecia in women of African ancestry.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
10 citations
,
September 1997 in “Molecular carcinogenesis” Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.
9 citations
,
October 2022 in “Nature Communications” The DiLiCre mouse model is an effective tool for precise genome editing using light.
A new microneedle patch helps repair spinal cord injuries by reducing scarring and promoting nerve growth.
2 citations
,
July 2017 in “Oncology Letters” Lacking cyclin D3 reduces skin cancer growth without affecting normal skin cell growth.